Quarterly report pursuant to Section 13 or 15(d)

Related Party Transactions (Tables)

v2.4.0.8
Related Party Transactions (Tables)
3 Months Ended
Mar. 31, 2014
Related Party Transactions [Abstract]  
Summary of activities related to related party
Milestones
 
Payments
 
       
(1) filing of an New Drug Application (“NDA”) or regulatory approval for each licensed product
 
$
750,000
 
(2) upon the receipt of regulatory approval from the U.S. FDA for each licensed product
   
1,750,000